Clinuvel Pharmaceuticals (FRA:UR9) Total Current Assets : €136.98 Mil (As of Jun. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Clinuvel Pharmaceuticals's total current assets for the quarter that ended in Jun. 2024 was €136.98 Mil.

Clinuvel Pharmaceuticals Total Current Assets Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Total Current Assets Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Total Current Assets

Get a 7-Day Free Trial

46.06

65.26

93.46

117.46

136.98

Clinuvel Pharmaceuticals Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Current Assets	Get a 7-Day Free Trial															93.46	99.89	117.46	123.68	136.98

Clinuvel Pharmaceuticals Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Clinuvel Pharmaceuticals's Total Current Assets for the fiscal year that ended in Jun. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	113.422	+	16.185	+	6.555	+	0.822
	=	136.98

Clinuvel Pharmaceuticals's Total Current Assets for the quarter that ended in Jun. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	113.422	+	16.185	+	6.555	+	0.822
	=	136.98

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Clinuvel Pharmaceuticals (FRA:UR9) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Clinuvel Pharmaceuticals's Liquidation Value for the quarter that ended in Jun. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	113.422	-	17.341	+	0.75 * 15.522	+	0.5 * 6.555
=	111.00

Clinuvel Pharmaceuticals Total Current Assets Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (FRA:UR9) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

CLVLY:USA CLVLF:USA UR9:Germany UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Clinuvel Pharmaceuticals Headlines

No Headlines